Finotonlimab

菲诺利单抗

Report date: 2026/05/20 20:02:01

Base Information

Drug NameFinotonlimab
Drug Alias Name重组人源化抗PD-1单克隆抗体注射液（神州细胞工程）安佑平SCT-I10ASCT-I10
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[7] 
Global Approved IndicationsSquamous Cell Carcinoma of Head and Neck
Approved Indications in ChinaSquamous Cell Carcinoma of Head and Neck
Original Approved Country/TerritoryMainland China
Original Approved Date2025/02/08
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSinoCelltech Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSinoCelltech Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursColorectal NeoplasmsSquamous Cell Carcinoma of Head and Neck +[6] 
Inactive IndicationsCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBank